December 2024- Cosmos Health, a diversified, vertically integrated global healthcare group engaged in innovative R&D, announced the appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology at the Company’s Research and Development division.

Professor Trafalis currently serves as a Professor of Pharmacology and Clinical Pharmacology at the Faculty of Medicine, National and Kapodistrian University of Athens.

He is a medical specialist in oncology-hematology, cancer cytogenetics, personalized cancer therapies, and clinical pharmacology, as well as an expert in biosciences, cancer research, drug design and development, and pharmacological innovations. He has authored multiple scientific publications in high-impact journals and received numerous citations for his work, focusing fully on experimental and clinical pharmacology and significantly advancing medical education and research in oncology and pharmacology. He has received several distinctions and grants from international research programs for his work. He holds degrees in Biology and Medicine, along with advanced postgraduate training.

Professor Trafalis will lead research initiatives focusing on the design and execution of preclinical and clinical development strategies, regulatory support, and cutting-edge studies aimed at addressing critical oncology challenges.

Also Read : Brian Harte Named President of Cleveland Clinic’s East Submarket

Professor Trafalis stated: “I am excited to join Cosmos Health in its mission to advance oncology research and deliver life-changing treatments to patients worldwide, and I have great expectations for a high-performance collaboration. I truly believe that the project of Cosmos Health could serve the purpose of curing individuals with cancer in advanced stages.”

Greg Siokas, CEO of Cosmos Health, stated: “We are honored to welcome Professor Trafalis, a distinguished oncology leader, to spearhead our research initiatives. His expertise in clinical development will accelerate our efforts to address unmet medical needs and deliver transformative therapies to patients globally.”